Skip to content
21 November · 06:30 UTCFollow GSK by emailFollow

GSK · Pharma and healthcare · one day

GSK (GSK): news on Saturday 21 November 2026

News from the 24 hours to Saturday morning, 21 November 2026.

Tone of the day

+7.2strongly positive
Relevant headlines11of 14 read
Stories6grouped by event

What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

Why it scored this way

Coverage was mainly positive, led by FDA approval of a lung cancer treatment and an early approval for Nelkarmi. Further support came from a Japanese orphan designation, encouraging tuberculosis trial data, a new Singapore facility and a modest share price rise.

What drove it

  • FDA approvals
  • pipeline progress
  • share price gains

Around this day

DayToneHeadlines
Sun 15 Nov+7.06
Mon 16 Nov+2.54
Tue 17 Nov+5.78
Wed 18 Nov+7.536
Thu 19 Nov0.01
Fri 20 Nov+6.322
Sat 21 Nov+7.211

6 stories · 11 headlines · strongest first

Pharma and healthcare on 21 NovemberFTSE 100 that day
ToneWhat the article reported, and why it scored that waySource
GSK news coverage +9.42 headlines today · 28 in all, since 18 November · Coverage of FDA approval of GSK's lung cancer treatment.
+10.0Regulatory clearance for a lung cancer therapy opens a new market.Labroots (opens the article) ↗
+9.2Early regulatory approval of a new product is a positive.Kalkine Media (opens the article) ↗
BioVersys-GSK antibiotic combination shows promise in TB trial +6.42 headlines today · A GSK-partnered antibiotic combo showed promise in a Phase II TB trial.
+7.0Shares helped by positive tuberculosis drug trial news.MarketScreener (opens the article) ↗
+5.8Partnered tuberculosis antibiotic combination showed encouraging mid-stage trial data.Clinical Trials Arena (opens the article) ↗
GSK share outlook and market commentary +0.62 headlines today · 13 in all, since 17 November · Pieces discuss a 1.6% share rise and the new FTSE session.
+6.7Share price rose, with coverage looking at the cause.Traders Union (opens the article) ↗
+0.8Market session preview with little substance on the company.Kalkine Media (opens the article) ↗
Japan gives velzatinib orphan designation for GIST +5.92 headlines today · 10 in all, since 20 November · Japanese authorities designated GSK's velzatinib an orphan drug in GIST.
+6.7Japanese designation for a rare-tumour drug, with recent share gains.Traders Union (opens the article) ↗
+6.3Special regulatory designation in Japan supports a pipeline drug.AD HOC NEWS (opens the article) ↗
GSK transfers treasury shares to back awards +0.22 headlines today · GSK transferred treasury shares to JPMorgan for ADRs to back award plans.
+0.3Routine treasury share transfer to fund employee award plans.TipRanks (opens the article) ↗
0.0Administrative filing about shares backing staff incentive plans.Stock Titan (opens the article) ↗
GSK launches high-potency production site in Singapore +5.81 headline today · GSK opened a high-potency drug facility in Singapore.
+5.8New manufacturing site expands capacity for cancer medicines.Singapore Economic Development Board (EDB) (opens the article) ↗

Each article has its own score. The lines are our own summary; follow the source link to read the article itself.

Follow by email

A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 21 November · 589 headlines · 93 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt